Atea Pharmaceuticals (AVIR) investor relations material

Executive summary

• Advanced global Phase III HCV program with bemnifosbuvir/ruzasvir; topline results from C-BEYOND expected mid-2026 and C-FORWARD by year-end 2026.

• Expanded antiviral pipeline with HEV program; lead candidate AT-587 shows potent in vitro and in vivo activity, with first-in-human studies expected mid-2026.

• Commercial readiness for HCV regimen underway, including manufacturing, marketing plans, and a focused specialty sales force.

• Strong financial position with $301.8 million in cash and equivalents as of December 31, 2025, supporting operations through 2027.

• Physician KOLs and market research highlight the need for optimized HCV regimens to support test-and-treat models.

Financial highlights

• Cash and investments totaled $301.8 million at year-end 2025, down from $454.7 million at year-end 2024.

• Net loss for 2025 was $158.4 million, with net loss per share of $1.94.

• R&D expenses increased to $148.0 million in 2025, driven by HCV Phase III development; G&A expenses decreased to $32.9 million due to lower stock-based compensation.

• $25 million returned to stockholders via share repurchase in 2025.

• Working capital at year-end 2025 was $271.2 million.

Outlook and guidance

• Topline Phase III HCV results from C-BEYOND expected mid-2026 and C-FORWARD by year-end 2026.

• NDA submission for bemnifosbuvir/ruzasvir anticipated in Q1 2027.

• First-in-human study for HEV candidate AT-587 anticipated mid-2026, with proof of concept by year-end or in 2027.

• Cash runway projected through 2027.